Sender Company & Partners’s iShares Biotechnology ETF IBB Stock Holding History

Sender Company & Partners’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.08M	Buy	+16,209	New	+$2.79M	0.89%	29

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Commerce Bank Kansas City, Missouri $22.8B AUM 28.56% 1-Year Est. Return

Sender Company & Partners's IBB Position: Q2 2026 in Review

Sender Company & Partners opened a new position in iShares Biotechnology ETF (IBB) in Q2 2026: 16,209 shares worth $3.08M. The stake represents 0.89% of the portfolio and ranks #29 among its holdings.

954 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

Sender Company & Partners held 16,209 shares of iShares Biotechnology ETF worth $3.08M as of Q2 2026.
iShares Biotechnology ETF was a new Sender Company & Partners position in Q2 2026.
iShares Biotechnology ETF made up 0.89% of Sender Company & Partners's portfolio in Q2 2026, its #29 holding.
954 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on Sender Company & Partners's 13F filing for Q2 2026, filed 14 Aug 2026.